185 related articles for article (PubMed ID: 33196045)
1. APOBEC3 enzymes mediate efficacy of cisplatin and are epistatic with base excision repair and mismatch repair in platinum response.
Conner KL; Shaik AN; Marshall KA; Floyd AM; Ekinci E; Lindquist J; Sawant A; Lei W; Adolph MB; Chelico L; Siriwardena SU; Bhagwat A; Kim S; Cote ML; Patrick SM
NAR Cancer; 2020 Dec; 2(4):zcaa033. PubMed ID: 33196045
[TBL] [Abstract][Full Text] [Related]
2. HPV induction of APOBEC3 enzymes mediate overall survival and response to cisplatin in head and neck cancer.
Conner KL; Shaik AN; Ekinci E; Kim S; Ruterbusch JJ; Cote ML; Patrick SM
DNA Repair (Amst); 2020 Mar; 87():102802. PubMed ID: 31981740
[TBL] [Abstract][Full Text] [Related]
3. Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity.
Kothandapani A; Sawant A; Dangeti VS; Sobol RW; Patrick SM
Nucleic Acids Res; 2013 Aug; 41(15):7332-43. PubMed ID: 23761438
[TBL] [Abstract][Full Text] [Related]
4. Differential role of base excision repair proteins in mediating cisplatin cytotoxicity.
Sawant A; Floyd AM; Dangeti M; Lei W; Sobol RW; Patrick SM
DNA Repair (Amst); 2017 Mar; 51():46-59. PubMed ID: 28110804
[TBL] [Abstract][Full Text] [Related]
5. Novel role of base excision repair in mediating cisplatin cytotoxicity.
Kothandapani A; Dangeti VS; Brown AR; Banze LA; Wang XH; Sobol RW; Patrick SM
J Biol Chem; 2011 Apr; 286(16):14564-74. PubMed ID: 21357694
[TBL] [Abstract][Full Text] [Related]
6. Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links.
Sawant A; Kothandapani A; Zhitkovich A; Sobol RW; Patrick SM
DNA Repair (Amst); 2015 Nov; 35():126-36. PubMed ID: 26519826
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
8. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system.
Perego P; Caserini C; Gatti L; Carenini N; Romanelli S; Supino R; Colangelo D; Viano I; Leone R; Spinelli S; Pezzoni G; Manzotti C; Farrell N; Zunino F
Mol Pharmacol; 1999 Mar; 55(3):528-34. PubMed ID: 10051537
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide mapping of regions preferentially targeted by the human DNA-cytosine deaminase APOBEC3A using uracil-DNA pulldown and sequencing.
Sakhtemani R; Senevirathne V; Stewart J; Perera MLW; Pique-Regi R; Lawrence MS; Bhagwat AS
J Biol Chem; 2019 Oct; 294(41):15037-15051. PubMed ID: 31431505
[TBL] [Abstract][Full Text] [Related]
10. Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells.
Ferry KV; Fink D; Johnson SW; Nebel S; Hamilton TC; Howell SB
Biochem Pharmacol; 1999 Apr; 57(8):861-7. PubMed ID: 10086318
[TBL] [Abstract][Full Text] [Related]
11. Binding discrimination of MutS to a set of lesions and compound lesions (base damage and mismatch) reveals its potential role as a cisplatin-damaged DNA sensing protein.
Fourrier L; Brooks P; Malinge JM
J Biol Chem; 2003 Jun; 278(23):21267-75. PubMed ID: 12654906
[TBL] [Abstract][Full Text] [Related]
12. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells.
Perego P; Gatti L; Caserini C; Supino R; Colangelo D; Leone R; Spinelli S; Farrell N; Zunino F
J Inorg Biochem; 1999 Oct; 77(1-2):59-64. PubMed ID: 10626355
[TBL] [Abstract][Full Text] [Related]
13. DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers.
Mas-Ponte D; Supek F
Nat Genet; 2020 Sep; 52(9):958-968. PubMed ID: 32747826
[TBL] [Abstract][Full Text] [Related]
14. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
15. The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast.
McA'Nulty MM; Lippard SJ
Mutat Res; 1996 Jan; 362(1):75-86. PubMed ID: 8538651
[TBL] [Abstract][Full Text] [Related]
16. Non-canonical uracil processing in DNA gives rise to double-strand breaks and deletions: relevance to class switch recombination.
Bregenhorn S; Kallenberger L; Artola-Borán M; Peña-Diaz J; Jiricny J
Nucleic Acids Res; 2016 Apr; 44(6):2691-705. PubMed ID: 26743004
[TBL] [Abstract][Full Text] [Related]
17. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.
Mello JA; Acharya S; Fishel R; Essigmann JM
Chem Biol; 1996 Jul; 3(7):579-89. PubMed ID: 8807890
[TBL] [Abstract][Full Text] [Related]
18. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins.
Kaspárková J; Brabec V
Biochemistry; 1995 Sep; 34(38):12379-87. PubMed ID: 7547982
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
[TBL] [Abstract][Full Text] [Related]
20. Preclinical perspectives on platinum resistance.
Kelland LR
Drugs; 2000; 59 Suppl 4():1-8; discussion 37-8. PubMed ID: 10864225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
